Metabolic Synchronization for Cancer Stem Cell Eradication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies face challenges in selectively eradicating cancer stem cells due to their unique genetic profiles and metabolic differences from normal cells, leading to recurrence and resistance, necessitating a novel approach that targets mitochondrial biogenesis and glycolytic metabolism.
Innovation Solution
Combining inhibitors of oxidative metabolism, such as tetracyclines and erythromycins, with inhibitors of glycolytic metabolism, like 2-deoxy-glucose and autophagy inhibitors, to metabolically 'starve' cancer stem cells by synchronizing their metabolic phenotype from oxidative to glycolytic, making them susceptible to additional metabolic stressors for eradication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional cancer therapies (irradiation, alkylating agents, anti-metabolites) are used to eradicate fast-growing cancer cells, then cell growth and DNA replication are interfered with, but tumors often recur indicating that not all cancer cells are eradicated
Solution Approach 1:
The patent changes the therapeutic parameter from targeting DNA replication to targeting metabolic pathways. By identifying and exploiting the unique metabolic dependencies of cancer stem cells (oxidative metabolism and glycolysis), the treatment achieves more complete eradication and prevents recurrence by addressing the root metabolic vulnerability of CSCs rather than just their proliferative capacity
Solution Approach 2:
The patent uses transcriptional profiling data and proteomic analysis to identify metabolic signatures that copy or reflect the unique metabolic state of cancer stem cells. By analyzing gene expression patterns and protein levels related to mitochondrial biogenesis and glycolysis, the treatment creates a metabolic profile that specifically identifies and targets CSCs for eradication
2Ease of operation
If immunotherapies (monoclonal antibodies) are used to selectively bind mutant tumor antigens on fast-growing cancer cells, then selective binding is achieved, but relapse occurs due to insufficient chemotherapeutic dosage and/or emergence of resistant clones
Solution Approach 1:
The patent changes the targeting parameter from surface antigen recognition to metabolic pathway inhibition. By targeting the metabolic dependencies (oxidative metabolism and glycolysis) that are fundamental to cancer stem cell survival, the treatment overcomes resistance and relapse issues that plague antigen-based immunotherapies, as metabolic vulnerabilities are more universal and less prone to mutation-driven resistance
Solution Approach 2:
The patent performs preliminary metabolic synchronization by exposing cancer stem cells to antibiotics that shift their metabolism from oxidative to glycolytic pathways. This preliminary metabolic reprogramming makes the cells uniformly dependent on glycolysis, thereby sensitizing them to subsequent glycolysis inhibitors and preventing the emergence of resistant clones
3Productivity
If antibiotics (tetracyclines, erythromycins) are used to inhibit mitochondrial biogenesis, then oxidative metabolism is suppressed, but cancer stem cells metabolically synchronize to glycolytic metabolism resulting in metabolic inflexibility and survival
Solution Approach 1:
The patent converts the harmful adaptation of metabolic inflexibility into a beneficial vulnerability. By allowing cancer stem cells to synchronize to glycolytic metabolism in response to mitochondrial inhibition, the treatment creates a uniform metabolic dependency that can be exploited by subsequent glycolysis inhibitors, turning the cells' survival mechanism into their Achilles' heel
Solution Approach 2:
The patent uses mitochondrial biogenesis inhibitors as a preliminary step to reprogram the metabolic state of cancer stem cells. This preliminary action synchronizes their metabolism to glycolysis, making them uniformly susceptible to subsequent glycolysis inhibition and preventing them from maintaining metabolic flexibility during treatment
4Adaptability or versatility
If a single tumor contains multiple divergent clone cells with unique genetic profiles, then tumor heterogeneity increases, but a single therapy cannot eradicate all clone types
Solution Approach 1:
The patent applies a universal metabolic targeting strategy that functions across diverse cancer clone types. By identifying metabolic dependencies (oxidative metabolism and glycolysis) that are common to all cancer stem cells regardless of their genetic mutations, the treatment achieves broad-spectrum efficacy against heterogeneous tumor populations, eradicating all clones through their shared metabolic vulnerability
Data Source
AI summary
The present disclosure relates to compounds and methods of eradicating cancer stem cells by combining inhibitors of oxidative metabolism and glycolytic metabolism. Also described are compounds and methods of identifying a combination of inhibitors of oxidative metabolism and glycolytic metabolism to treat cancer stem cells.